CN111212836B - 赖氨酰氧化酶抑制剂 - Google Patents

赖氨酰氧化酶抑制剂 Download PDF

Info

Publication number
CN111212836B
CN111212836B CN201880065806.5A CN201880065806A CN111212836B CN 111212836 B CN111212836 B CN 111212836B CN 201880065806 A CN201880065806 A CN 201880065806A CN 111212836 B CN111212836 B CN 111212836B
Authority
CN
China
Prior art keywords
optionally substituted
cancer
lox
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880065806.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111212836A (zh
Inventor
理查德·马雷
卡洛琳·施普林格
丹·尼库雷斯库-杜沃兹
娜塔莉·米勒
穆罕默德·阿尔贾拉
阿方索·赞邦
梁文颢
黛博拉·斯密滕
迈克尔·布朗
唐浩然
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANCER RESEARCH INSTITUTE
Original Assignee
CANCER RESEARCH INSTITUTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANCER RESEARCH INSTITUTE filed Critical CANCER RESEARCH INSTITUTE
Publication of CN111212836A publication Critical patent/CN111212836A/zh
Application granted granted Critical
Publication of CN111212836B publication Critical patent/CN111212836B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880065806.5A 2017-10-13 2018-10-12 赖氨酰氧化酶抑制剂 Active CN111212836B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1716871.7A GB201716871D0 (en) 2017-10-13 2017-10-13 Compounds
GB1716871.7 2017-10-13
PCT/GB2018/052934 WO2019073251A1 (en) 2017-10-13 2018-10-12 INHIBITORS OF LYSYL OXIDASE

Publications (2)

Publication Number Publication Date
CN111212836A CN111212836A (zh) 2020-05-29
CN111212836B true CN111212836B (zh) 2023-12-15

Family

ID=60419229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065806.5A Active CN111212836B (zh) 2017-10-13 2018-10-12 赖氨酰氧化酶抑制剂

Country Status (8)

Country Link
US (2) US11325915B2 (https=)
EP (1) EP3694857A1 (https=)
JP (1) JP7385561B2 (https=)
CN (1) CN111212836B (https=)
CA (1) CA3076566A1 (https=)
GB (1) GB201716871D0 (https=)
IL (1) IL273727B2 (https=)
WO (1) WO2019073251A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112533897B (zh) 2018-08-03 2023-07-14 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途
GB201818750D0 (en) * 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
AU2020317374A1 (en) * 2019-07-25 2022-02-03 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US12578335B2 (en) 2020-02-05 2026-03-17 Syntara Limited Bioprobes for lysyl oxidases and uses thereof
US20230310445A1 (en) * 2020-04-21 2023-10-05 Anovia Biosciences, Inc. Lox enzyme inhibiting methods and compositions
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies
CN116763899B (zh) * 2023-07-17 2026-02-24 大连医科大学附属第一医院 Htra1抑制剂在制备治疗胰腺炎-癌转化的药物中的应用
CN119732928B (zh) * 2024-12-26 2026-04-07 国家纳米科学中心 一种抑制胶原纤维形成的药物分子及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008517A2 (en) * 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2016085783A1 (en) * 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
WO2016144846A1 (en) * 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
CN106255684A (zh) * 2013-11-14 2016-12-21 诺维拉治疗公司 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
WO2017003862A1 (en) * 2015-07-01 2017-01-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992546A (en) 1987-07-31 1991-02-12 Warner-Lambert Company Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives
DE4402933A1 (de) 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
JP6849197B2 (ja) 2016-02-12 2021-03-24 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
US20210009551A1 (en) 2016-06-02 2021-01-14 The Regents Of The University Of California Compounds and methods for treating fibrosis or cancer
WO2018048928A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Chemical probes of lysyl oxidase-like 2 and uses thereof
WO2018048930A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
KR102587178B1 (ko) 2016-09-07 2023-10-06 파마케아, 인크. 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법
US20200069648A1 (en) 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008517A2 (en) * 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
CN106255684A (zh) * 2013-11-14 2016-12-21 诺维拉治疗公司 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
WO2016085783A1 (en) * 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
WO2016144846A1 (en) * 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
WO2017003862A1 (en) * 2015-07-01 2017-01-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《A general and efficient synthesis of 3,6-diazabicyclo[3.2.1]octanes》;Singh, Rakesh K.;《Tetrahedron》;20060303;第62卷(第17期);参见第4012-4013页化合物6c、7a-7h *
《Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol》;Peprah, Kwakye;《Bioorganic & Medicinal Chemistry》;20120111;第20卷(第5期);参见第1672页化合物5 *

Also Published As

Publication number Publication date
US20200331922A1 (en) 2020-10-22
EP3694857A1 (en) 2020-08-19
GB201716871D0 (en) 2017-11-29
US12060360B2 (en) 2024-08-13
US11325915B2 (en) 2022-05-10
CA3076566A1 (en) 2019-04-18
US20220289757A1 (en) 2022-09-15
WO2019073251A1 (en) 2019-04-18
JP2020536924A (ja) 2020-12-17
IL273727B2 (en) 2023-06-01
CN111212836A (zh) 2020-05-29
JP7385561B2 (ja) 2023-11-22
IL273727A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CN111212836B (zh) 赖氨酰氧化酶抑制剂
CN113365984B (zh) Lox抑制剂
JP2025037925A (ja) 協同的結合に関与する化合物及びその使用
KR20240004960A (ko) Ras 억제제
CN117715658A (zh) 抑制ras的方法
AU2024360465A1 (en) Macrocyclic ras inhibitors
WO2017141049A1 (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
US12018029B2 (en) Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors
JP2022507561A (ja) Ａｍ２受容体阻害剤としての複素環スピロ化合物
JP2022507559A (ja) Ａｍ２受容体阻害剤としての複素環スピロ化合物
BR122019019002B1 (pt) Processo de fabricação de compostos de pirazolo[1,5-a]piridina substituídos e kit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant